COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

Abstract

Background and purpose In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well‐designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS‐2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non‐Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non‐motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions Parkinson's disease is a complex disorder and different non‐motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.

Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease

“…Previous studies have explored the frequency of NMS and motor complications in PD and our results [4] are aligned with them [7‐9]. Although previous reports demonstrated that approximately 40% of patients with PD who were treated with levodopa for 4–6 years experienced motor complications [10], studies examining wearing‐off more specifically have observed that this is a potentially early phenomenon, affecting 42% of patients with PD with <2.5 years of disease when a screening tool was used (self‐rated 19‐question Wearing‐Off Questionnaire) and 21% according to neurologist assessment [11].…”

“…Patients with PD from the COPPADIS cohort [4,5] were included in this study. Methodology can be consulted in https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-016-0548-9 [5].…”

Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

“…The presented data correspond to the cross-sectional evaluation at baseline of COPPADIS cohort, nevertheless, the assessment of the ICDs/CBs behaviour over time would be more informative. This issue would be overcome in the future since the follow up of this cohort is on-going and we will obtain the longitudinal data 38 . On the other hand, following the methodology of the study, the UPDRS part II evaluation only included motor items to assess the phenotype (tremor dominant, postural instability and gait disorders or undetermined).…”

Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up

“…PD patients and controls, who were recruited from January 2016 to November 2017 from 35 centers of Spain from the COPPADIS cohort [ 14 ] and were evaluated again at 2-year follow-up, were included in the study. Methodology about COPPADIS-2015 study can be consulted at (25 February 2016) [ 15 ].…”